Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Heplisav Postmarketing Worries Push PDUFA Date Back; FDA Seeks More Details

Executive Summary

Dynavax's final pivotal trial for hepatitis B candidate was missing data from 150 patients, making its causality of myocardial infarctions unclear; the question now is whether the postmarketing trial can answer the question.

Advertisement

Related Content

Finance Watch: Roivant Raises $1.1bn, Relying On Private Equity To Fund New Companies
Don't Lose Track: Review And Approval News On Opdivo, Kalydeco And More
Heplisav Seems Headed For Approval, But With More Robust Postmarketing Study
Heplisav Vaccine Postmarketing Study Might Overcome FDA Safety Worries At Panel

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS121266

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel